IMO this comes down to matter of style: The are tw
Post# of 147673
Unfortunately, neither one seems to fair any better or worse when they run up against the Big Pharma/FDA establishment no matter how their drug works. Both are slow walked, both are sent FDA warning letters, both have fake law suits, both are harassed by bashers and media hack.
Would the SP be worse if NP were still on, who knows, but I think he would be hyping the next thing which gives investors hope which keeps the price up. Just a matter of style, the results are the same no approval if you're not Gilead. Maybe NP could swing a deal for BO better?
I still think NASH is out the for sale!